Retatrutide
aka Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)
Mechanism
Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).
Identification
| CAS number | 2381089-83-2 |
|---|---|
| Molecular formula | C221H342N46O68 |
| Sequence | YXQGTFTSDYSIXLDKKAQXAFIEYLLEGGPSSGAPPPS |
| Typical dose | 0.5–12 mg once weekly subcutaneous (Phase 2 titration; 2–8 mg most studied maintenance range) |
| Half-life | ~6 days |
Vendors selling Retatrutide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Partners | 48 mg | $273.00 | — | 99 |
| Crush Research | 20 mg | $76.33 | — | 95 |
| Crush Research | 50 mg | $116.33 | — | 95 |
| Crush Research | 10 mg | $129.00 | — | 95 |
| Crush Research | 15 mg | $199.00 | — | 95 |
| Crush Research | 30 mg | $249.00 | — | 95 |
| Orbitrex Peptides | 10 mg | $79.99 | — | 95 |
| Orbitrex Peptides | 20 mg | $129.99 | — | 95 |
| Orbitrex Peptides | 30 mg | $210.00 | — | 95 |
| Orbitrex Peptides | 36 mg | $219.99 | — | 95 |
| Profound Aminos | 5 mg | $69.00 | — | 95 |
| Prime Peptides | 10 mg | $120.00 | — | 95 |
| Prime Peptides | 30 mg | $120.00 | — | 95 |
| Prime Peptides | 60 mg | $120.00 | — | 95 |
| Amino Club | 30 mg | $179.99 | — | 93 |
| Skye Peptides | 12 mg | $90.00 | — | 90 |
| Qihang Peptide | — | — | — | 87 |
| Peptidegurus | 10 mg | — | — | 84 |
| Peptidegurus | 20 mg | — | — | 84 |
| Peptidegurus | 30 mg | — | — | 84 |
| Reta Peptide | 10 mg | $135.00 | — | 83 |
| Cocer Peptides | 10 mg | $200.00 | — | 82 |
| Cocer Peptides | 30 mg | $430.00 | — | 82 |
| Cocer Peptides | 40 mg | $480.00 | — | 82 |
| Cocer Peptides | 50 mg | $580.00 | — | 82 |
| Blank Peptides | 10 mg | $130.00 | — | 81 |
| Blank Peptides | 20 mg | $130.00 | — | 81 |
| Blank Peptides | 30 mg | $130.00 | — | 81 |
| Crystal Peptides | 10 mg | $99.00 | — | 66 |
| Crystal Peptides | 20 mg | $159.99 | — | 66 |
| Crystal Peptides | 30 mg | $199.00 | — | 66 |
| Peptiatlas | — | — | — | 51 |
| Peptiatlas | — | — | — | 51 |
| Taishijie | — | — | — | 51 |
| Taikangbio | — | — | — | 50 |
| Zjpeptix | — | — | — | 50 |
| Hkuppeptide | 10 mg | $10.00 | — | 50 |
| Hkuppeptide | — | $10.00 | — | 50 |
| Hkuppeptide | 10 mg | $10.00 | — | 50 |
| Hkuppeptide | 5 mg | $10.00 | — | 50 |
| Hkuppeptide | 15 mg | $10.00 | — | 50 |
| Hkuppeptide | 10 mg | $10.00 | — | 50 |
| MEI-PEPETIDE | 5 mg | $120.00 | — | 48 |
| DongCheng Peptide | — | — | — | 46 |
| Mandy | 5 mg | $45.00 | — | 43 |
| HongDa Peptide | — | $77.00 | — | 43 |
| zztai Peptide Ltd | 5 mg | $110.00 | — | 43 |
| zztai Peptide Ltd | 10 mg | $170.00 | — | 43 |
| zztai Peptide Ltd | 15 mg | $206.00 | — | 43 |
| zztai Peptide Ltd | 20 mg | $240.00 | — | 43 |
| zztai Peptide Ltd | 30 mg | $280.00 | — | 43 |
| MJT peptides | 5 mg | $70.00 | — | 39 |
| HK Peptide Ltd (hk peptides) | 10 mg | $145.00 | — | 37 |
| Alpha Peptides | — | — | — | — |
| Cernum Biosciences | 5 mg | $94.99 | — | — |
| Cernum Biosciences | 10 mg | $94.99 | — | — |
| Cernum Biosciences | 15 mg | $94.99 | — | — |
| Cernum Biosciences | 20 mg | $94.99 | — | — |
| NG Peptide | 10 mg | $42.00 | — | — |
| Strate Labs | 60 mg | $299.00 | — | — |
| Bulk Peptides | 20 mg | $600.00 | — | — |
| Bulk Peptides | 10 mg | $360.00 | — | — |
| Polaris Peptides | 60 mg | $400.00 | — | — |
| Polaris Peptides | 10 mg | $89.00 | — | — |
| Polaris Peptides | 35 mg | $275.00 | — | — |
| Polaris Peptides | 5 mg | $50.00 | — | — |
| Polaris Peptides | 15 mg | $130.00 | — | — |
| realpeptides.co | — | $130.00 | — | — |
Research
Diabetes mellitus is associated with cognitive impairment and neurodegenerative changes, partly through hyperglycaemia-driven neuroinflammation and disrupted neuronal signalling.
source →Introduction It has been reported that glucagon-like peptide-1 (GLP-1) agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists exert beneficial effects on blood pressure and lipid profile.
source →Background Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications.
source →Retatrutide is a novel triple agonist that targets the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R).
source →Background and hypothesis Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors that reduced weight and hemoglobin A1c (HbA1c) in individuals with obesity and type 2 diabetes (T2D).
source →Context In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D. Objective Assess plasma metabolome and lipidome changes associated with retatrutide treatment.
source →Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.
source →BACKGROUND: Retatrutide, a novel GIP, GLP-1, and glucagon receptor triple agonist, exhibits unprecedented weight-reducing efficacy in clinical trials, yet the molecular basis of its systemic metabolic benefits remains unclear.
source →Adolescent obesity is an escalating global health concern associated with increased risks of cardiovascular disease, type 2 diabetes mellitus, and long-term metabolic complications.
source →Objective/methods Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
source →The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants.
source →The purpose of this study is to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during hypoglycemic clamp in participants with Type 2 Diabetes Mellitus (T2DM) following 16 weeks of treatment.
source →Phase 2 RCT: retatrutide reduced liver fat in metabolic-dysfunction-associated steatotic liver disease (MASLD).
source →Network meta-analysis comparing GLP-1 receptor agonists and polyagonists (including retatrutide) for weight loss.
source →Phase 2 RCT: the triple GIP/GLP-1/glucagon agonist retatrutide produced large, dose-dependent weight loss (~24% at the top dose) over 48 weeks.
source →The study is conducted in two parts (Part A and B).
source →The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function.
source →The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
source →The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese.
source →The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1).
source →The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
source →